CGEN Compugen Ltd.

NASDAQ
$2.38

Compugen Ltd. (CGEN) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.7% since its last earnings release on August 3, 2026.

Compugen Reported In-line with Estimates
Monday, August 3, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.08)
Rev est $2.7M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.54

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Compugen Ltd.

Compugen Ltd is a drug discovery and development company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.